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INTRODUCTION
Osteosarcoma is the most common malignant bone tumor in children and adolescents, with approximately 400 new cases each year in the United States (Ottaviani and Jaffe, 2009 ).
Although most cases are sporadic, the risk of osteosarcoma is increased in patients with various genetic diseases, including hereditary retinoblastoma, Li Fraumeni syndrome, and germline mutations of RecQL4 (Hicks et al., 2007; Kleinerman et al., 2005; McIntyre et al., 1994) . Current multimodal therapies that incorporate surgical excision and combination chemotherapy (i.e., doxorubicin, methotrexate, and cisplatin) cure approximately 70% of patients (Meyers et al., 2005) . However, clinical outcomes and therapeutic strategies have remained virtually unchanged over the past 20 years (Smith et al., 2010) .
In this study, we characterized the genomic landscape of osteosarcoma by performing whole-genome sequencing (WGS) on 34 osteosarcoma tumor and matched nontumor tissue samples from 32 patients. Our results demonstrate that pediatric osteosarcomas have one of the highest rates of SVs of any pediatric cancer sequenced to date (Downing et al., 2012) , but relatively few recurrent single-nucleotide variations (SNVs). However, when SVs and SNVs were combined, inactivating mutations were identified in several cancer pathways. Taken together, our results provide insights into the molecular pathology of pediatric osteosarcoma and demonstrate that comprehensive WGS is required to elucidate the complete genetic landscape of osteosarcoma.
RESULTS

WGS of Primary and Metastatic Osteosarcomas
Using a paired-end sequencing approach, we generated 10,265 Gb of sequence data for DNA in 20 osteosarcomas and matched normal DNA from 19 osteosarcoma patients in a discovery cohort, and 14 tumor specimens and matched normal DNA from 13 patients in a validation cohort (Table S1 ); 9,671 Gb (94%) were successfully mapped to the reference genome (Table S2 ). In the discovery cohort, the samples included 17 pretreatment diagnostic samples (16 primary and one metastatic), one recurrent metastatic sample (SJOS001), and two tumor specimens (SJOS010_D and SJOS010_M) from the same patient with metachronous osteosarcoma (Table S1 ).
The average genome coverage was 443 and the average exon coverage was 393; 99% of SNPs detected across all 39 genomes showed concordance with their corresponding SNP array genotype calls (Table S2 ). Validation was carried out using custom liquid capture for all SNVs, SVs, and insertions or deletions (indels) identified in the original sequence data. Combining the discovery and validation cohorts, we identified 50,426 validated somatic sequence mutations and 10,806 SVs (Table S3 ). These included 856 nonsilent tier 1 mutations in genes, 4,651 tier 2 mutations in evolutionarily conserved regions of the genome, and 43,782 tier 3 mutations in nonrepetitive regions of the genome that are not part of tier 1 or tier 2 (Table S3 ). The average number of sequence mutations was 1,483.1 per case (range 610-5,178), with 25.2 mutations per case (range 5-103) resulting in amino acid changes (Table S3 ). The estimated mean mutation rate was 1.15 3 10 À6 per base (range 4.90 3 10 À7 -3.99 3 10 À6 ). Among the validated SVs, 377 were predicted to produce an in-frame fusion protein (Table S3) . Good-quality RNA sequencing (RNA-seq) data were available for five tumors with 64 predicted fusion SVs. Among them, 15 SVs (23%) were expressed (Table S3) . Primary and metastatic osteosarcomas had high rates of validated SVs ( Figures 1A and S1 ). The number of SVs and CNVs, background mutation rate, and number of nonsilent tier 1 mutations were significantly higher in osteosarcoma compared with medulloblastoma and T-ALL (Robinson et al., 2012; Zhang et al., 2012; Figure 1B) . However, only the number of SVs was significantly higher in osteosarcoma compared with another pediatric solid tumor with high rates of somatic alterations (embryonal rhabdomyosarcoma) (Chen et al., 2013; Figure 1B) . The global patterns revealed by the WGS analysis of osteosarcoma suggest that the majority of SVs and CNVs were generated by sequential accumulation of SVs ( Figures 1C and 1D ), but chromothripsis was detected at specific genomic regions in four samples (chr14 in SJOS002_D, chr17q in SJOS003_D, chr6q in SJOS005_D, and chr13 in SJOS010_M; Supplemental Experimental Procedures). We used a modified version of GISTIC analysis to identify regions of the osteosarcoma genome with recurrent copy number alterations in the discovery cohort. The TP53, RB1, MYC, and PTEN pathways, as well as ATRX, LSAMP-AS3, CCNE1, and a genomic region on chromosome 16 containing COPS3, PMP22, MAPK7, NCOR1, and UBB, were recurrently mutated ( Figure S1C ). Among SNVs with sufficient coverage in both SJOS010 samples (203), we validated 673 SNVs in both samples, 1,686 in diagnostic-only samples, and 1,408 in metastasis-only samples, indicating that these two tumors shared a limited amount of common mutations and were divergent early in the progression.
Applying the GRIN method (Pounds et al., 2013) on functional mutations (including SNVs and indels) and SVs, we identified TP53 (false discovery rate [FDR] = 3.6E-51, mutated in 28/34 samples) RB1 (FDR = 1.1E-5, mutated in 10/34 samples), ATRX (FDR = 2.4E-4, mutated in 10/34 samples), and DLG2 (FDR = 0.044, mutated in 18/34 samples) as significantly mutated genes. All genes except DLG2 were mutated by point mutations (nine for TP53, three for RB1, and five for ATRX) and SVs in multiple tumors (18 for TP53, seven for RB1, and five for ATRX). DLG2 was exclusively mutated by SVs.
Osteosarcoma Tumor Purity and Tumor Heterogeneity
Using the purity-adjusted mutant allele fraction (MAF) derived from deep sequencing of all SNVs by capture enrichment and Illumina sequencing, we analyzed intratumor heterogeneity. Eleven tumors (SJOS001_M, SJOS004, SJOS005, SJOS008, SJOS012, SJOS013, SJOS015, SJOS001103_D1, SJOS001105_D1, and SJOS001123_D1, and SJOS001125_D1) were excluded from quantitative heterogeneity analysis due to an insufficient number of SNVs in copy-neutral regions. Statistical modeling demonstrated that 61% (14/23) of osteosarcomas in this group had evidence of multiple clones, including metastatic samples SJOS010_M, SJOS001107_M1 and SJOS001107_M2 ( Figure S2 ).
Kataegis in Osteosarcoma
To determine whether there was any relationship between the SVs and location, distribution, or type of SNV in the osteosarcoma genomes, we plotted the validated SVs and SNVs for each sample and analyzed the intermutation distance ( Figure S2 ). Hypermutable regions with the five hallmarks of kataegis (NikZainal et al., 2012) were identified in 17 of the osteosarcoma tumors ( Figure 2A ). These five hallmarks of kataegis are (1) enriched C->T and C->G substitutions at TpCpX trinucleotides (Figures 2B and 2C) , (2) the same class of nucleotide mutation occurring for contiguous stretches before switching to a different class ( Figure 2D ), (3) mutations within short stretches of the genome occurring on the same parental chromosome (Figure S2 ), (4) clustering of heavily mutated short stretches of the genome at multiple scales ( Figure 2E ), and (5) association of the hypermutated region with SV breakpoints ( Figure 2E ). The regions of the genome with kataegis were not recurrent in our cohort and were not associated with recurrently mutated genes (B) Boxplots of validated basal mutation rate (BMR) and numbers of nonsilent SNVs, total SVs, and total CNVs in embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS) tumors in the discovery cohort. * represents statistical significance of p < 0.001 as compared with the osteosarcoma genomes. Chronology of Kataegis, SVs, and Aneuploidy in SJOS005 SJOS005 had the highest proportion (11%) of kataegis SNVs in our cohort. The large number of kataegis SNVs (n = 212) coupled with the accurate measurement of the MAFs of all SNVs derived from deep sequencing allowed us to analyze the chronology of kataegis in relation to other mutational events in this tumor. First, we examined MAFs of SNVs in kataegis microclusters containing five or more consecutive kataegis SNVs within 10 kb. The MAF variance was relatively small (6.7% of overall variance) within a microcluster, although there was a wide range of MAFs across microclusters (range 0.142-0.839, median 0.364; Figure S2 ). This pattern, along with the observation that SNVs in a microcluster occurred on the same parental chromosome, supports the hypothesis that SNVs in a kataegis microcluster originated from a single event. MAF analysis of SVs flanking ''kataegis'' clusters (range 0.132-0.866, median 0.396) also showed a significant positive correlation (p = 4.56E-5) with those of ''kataegis'' SNVs, and there was no significant difference between them (p = 0.143 by Wilcoxon signed rank test), indicating that the neighboring SVs likely arise simultaneously with kataegis SNVs ( Figure S2 ). See also Figure S3 and Table S4. SJOS005, like most osteosarcomas, exhibits aneuploidy with copy number gains spanning more than 50% of the genome. Kataegis SNVs were significantly enriched in regions of the genome with four or more copies compared with nonkataegis SNVs (p < 2.2e-16 by Fisher's exact test; Figure S2 ). However, the MAF distribution of kataegis SNVs showed a large fraction of SNVs with multiple copies of the mutant allele in amplified regions, whereas only a single copy of mutant alleles was found in the majority of the nonkataegis SNVs ( Figure S2 ). Taken together, these data suggest that kataegis likely occurs before global aneuploidy, and nonkataegis SNVs occur primarily after the aneuploidy.
SVs in TP53
The p53 pathway was mutated in all 20 tumor samples from the 19 patients in our discovery cohort. The majority (95%, 19/20) had either sequence mutations or SVs in the TP53 gene, and one (SJOS018) had an MDM2 amplification (see Figures 1C and 1D; Table S3) . Surprisingly, 55% of the tumors (11/20) had SVs in the TP53 gene, and the majority of those were translocations with breakpoints that were confined to the first intron of the gene (90%, 19/21 SV breakpoints; Figures 3A-3C; Table S4 ). Indeed, some tumors had rearrangements in both alleles of TP53, resulting from two or more independent translocations (Table S4) . One patient's tumor (SJOS006) had a germline SNV (R337H), one (SJOS012) had a somatic splice-site mutation, and two (SJOS004 and SJOS010) had somatic missense SNVs (Figures 3A-3C ; Table S4 ). The remaining four patients had tumors that harbored indels in the TP53 gene. Loss of heterozygosity (LOH) at the TP53 locus was evident in 40% (8/20) of the osteosarcoma tumors. In total, 15 tumors had biallelic inactivation of TP53, four had monoallelic inactivation of TP53, and one had MDM2 amplification ( Figure 1C ; Table S4 ).
To further validate the translocations in the TP53 gene identified by WGS, we developed a break-apart fluorescence in situ hybridization (FISH) assay with separate probes spanning the 5 0 and 3 0 regions of the gene ( Figure 4A ). We also developed a FISH assay with a probe spanning the entire TP53 gene ( Figure 4A ) to assess ploidy and determine whether the gene was deleted. To complement the FISH analysis, we performed p53 immunostaining to verify that the tumors with missense mutations had accumulated high levels of nuclear p53 protein.
We successfully performed FISH in 18 of 20 tumors and p53 immunostaining on all 20 tumors (Table S4) . Overall, there was perfect concordance between the WGS data and the FISH data (Figures 4B-4M ; Table S4 ). See also Table S5 .
In an additional cohort of patient tumor samples, we found that 50% (16/32) had TP53 rearrangements, 22% (7/32) had missense mutations, 16% (5/32) had nonsense mutations, 6% (2/32) had a TP53 deletion, and 3% (1/32) had an MDM2 amplification (Table S5 ). Three patients with tumor showed no evidence of a p53 pathway mutation.
We did not find any significant difference in CNV (p = 0.20 by Wilcoxon rank sum test), SV (p = 0.85), SNV (p = 0.43), nonsilent tier 1 mutations (p = 0.66), or background mutation rate (p = 0.43) in the osteosarcoma samples with mutant p53 versus those with inactivating (nonsense, deletion and truncation) mutations in TP53. Survival analysis, including eventfree survival and overall survival, did not show a significant difference in outcome for the patients whose tumors carried TP53-missense mutations (ten patients) versus those with TP53-truncating mutations (34 patients), with log rank test p values of 0.88 and 0.64, respectively. RB1, ATRX, and DLG2 Are Recurrently Mutated in Osteosarcoma ATRX is part of a multiprotein complex that regulates chromatin remodeling, nucleosome assembly, and telomere maintenance. It was recently shown that ATRX mutations in neuroblastoma are associated with age at diagnosis (Cheung et al., 2012) . Most neuroblastomas with ATRX mutations show evidence of alternative lengthening of telomeres (ALT), as measured by WGS, telomere FISH, and telomere quantitative PCR (qPCR) (Cheung et al., 2012) . In our osteosarcoma discovery cohort, we identified five tumors (SJOS001, SJOS002, SJOS007, SJOS001112-M2, and SJOS001117-D1) with point mutations in ATRX, and five SJOS001_M  SJOS010_M  SJOS002_D  SJOS007_D  SJOS006_D  SJOS005_D  SJOS004_D  SJOS003_D  SJOS012_D  SJOS011_D  SJOS010_D  SJOS009_D  SJOS008_D  SJOS017_D  SJOS016_D  SJOS015_D  SJOS014_D  SJOS013_D  SJOS019_D (A) Diagram of the five SNVs, four deletions, and one interchromosomal SV found in the ATRX genes of the osteosarcoma cohort. Three of the samples with ATRX SVs (SJOS006, SJOS018, and SJOS011) had matching RNA-seq data. SJ006 has a short deletion at exon 23 and the RNA-seq data confirmed a readthrough with focal deletions or SVs affecting the coding region of the gene ( Figure 5A ; Table S6 ). There was no significant gender bias in ATRX mutations (p = 0.25 by Fisher's exact test) even though it is located on the X chromosome. By immunohistochemistry, 31% (6/19) of the tumors in the discovery cohort were ATRX negative ( Figure 5B ; Table S6 ). The sample with a missense mutation (SJOS007-R1803C) and one with an SV (SJOS018) were heterogeneous for ATRX protein expression. Analysis of telomere sequence reads from the WGS data and qPCR of telomeres showed that the majority of osteosarcomas had longer telomeres ( Figures 5C and 5D) , and ALT was found in 85% (12/14) of the samples using telomere FISH (Table S6) .
Beyond TP53 and ATRX, there were significant recurrent mutations in RB1 (10/34, FDR q = 1.1E-5) and DLG2 (18/34, FDR q = 0.044). DLG2 encodes a multi-PDZ domain protein that is involved in epithelial polarity during cell division and has been implicated in cancer cell invasion. In Drosophila, DLG is a tumor suppressor, but a clear tumor-suppressor function has not yet been confirmed for DLG2 in human cancer.
SVs in Cancer Genes
SVs contributed 91% (9,605/10,523) of all functional genetic lesions in our osteosarcoma cohort. In total, 122 cancer genes had at least one SV breakpoint (Table S7 ) and all but one tumor (SJOS001118_D1) had at least one breakpoint (range 1-40) in a cancer gene. SV breakpoint enrichment in the cancer genes was highly significant even when we excluded TP53 from the list (p = 2.5E-6). Twelve of the 34 tumors (35%) achieved significant enrichment of SV breakpoints in cancer genes individually. In addition, some tumors have ''fold-back intrachromosomal translocations'' (Campbell et al., 2010) to inactivate tumorsuppressor genes ( Figure S3 ). These results further support the hypothesis that genomic instability leads to lesions in various cancer genes.
DISCUSSION
WGS of osteosarcoma demonstrated that the rate of SNVs was similar to that in other pediatric solid tumors, and only a few recurrent SNVs were detected. Approximately half of the osteosarcomas in our discovery cohort had a pattern of hypermutation associated with SVs, called kataegis (Nik-Zainal et al., 2012) . The regions of the genome with kataegis were not recurrent, and none of the most recurrently mutated genes were found in regions of kataegis. Chromosomal lesions, rather than SNVs, were the major mechanism of recurrent mutations, and many of the most significant chromosomal lesions were found in known cancer genes, including TP53, RB1, and ATRX.
Genomic Stability and Osteosarcoma Initiation and Progression
The most frequent mutation in osteosarcoma is in TP53. By our estimates, both alleles are mutated in as many as 80% of tumors, and at least one allele was mutated in >90% of tumors. These data suggest that p53 mutations are a major oncogenic driver in osteosarcoma. Although this finding is not novel, what is surprising is the mechanism of inactivation. Most TP53 mutations are SVs in intron 1, which suggests that either the TP53 locus is particularly susceptible to SVs or SVs occur at a high rate in the osteosarcoma tumor-initiating cell. Aside from osteosarcomas and prostate cancers (Baca et al., 2013; Berger et al., 2011) , there is no evidence of TP53 SVs in any other cancer, so the locus is probably not uniquely susceptible to chromosomal rearrangements. These data raise an intriguing possibility: genomic instability characterized by high rates of CNVs and SVs may precede TP53 inactivation, and may be the underlying mechanism that initiates and promotes osteosarcoma.
Kataegis in Osteosarcoma
In a recent WGS study, Nik-Zainal et al. (2012) described a distinct hypermutation phenomenon in breast cancer that they termed kataegis. Here, we found SNV clusters with the same five characteristics of kataegis in 50% of the osteosarcomas analyzed by WGS. Interestingly, genomic regions encoding TP53 and ATRX, the two most frequently mutated genes in osteosarcoma, did not exhibit this pattern of local hypermutation. Furthermore, there was no association between kataegis and TP53 mutation type (i.e., SNV, indel, or SV).
TP53-Mutant or -Null Osteosarcomas
Previous studies have estimated that 20%-70% of osteosarcomas carry mutations in the p53 pathway (Lonardo et al., 1997; Wunder et al., 2005) , but our data suggest that the proportion is much higher. For example, Wunder et al. (2005) sequenced exons 4-10 of the TP53 gene in 196 osteosarcoma samples and found that 19.4% (38/196) had TP53 SNVs. The investigators concluded that the remaining 80.6% (158/196) had wild-type TP53 (Wunder et al., 2005) . They went on to show that event-free survival was indistinguishable between the two groups (wild-type and mutant TP53) (Wunder et al., 2005) . SVs in the first intron of TP53 were not analyzed in that study, even though such lesions had previously been reported in osteosarcoma . Our data suggest that the majority of the tumors identified as TP53 wild-type in the study event that would result in a T1885 frameshift. For SJOS011, the RNA-seq and WGS data supported a junction connecting exon 1 to exon 28, creating a nonsense mutation (M6R*). For SJOS018, the RNA-seq and WGS data supported a deletion connecting exon 1 to exon 13, thereby creating an in-frame fusion protein (M6RS1406). The WGS for SJOS016 predicts a deletion that connects exon 1 to exon 16, producing a frameshift (M6fs). Tables S6 and S7. by Wunder et al. (2005) actually had inactivating SVs in TP53. Therefore, it may be useful to revisit the association of TP53 pathway inactivation with osteosarcoma outcome in a large cohort of patient samples.
EXPERIMENTAL PROCEDURES
Full details regarding sample acquisition, molecular and biochemical procedures, informatics, and WGS are provided in the Supplemental Information. All tumors in this study were obtained from St. Jude Children's Research Hospital (SJCRH) patients. The SJCRH IRB approved experiments involving human subjects and informed consent was obtained from all subjects.
ACCESSION NUMBERS
The European Bioinformatics Institute accession number for the sequencing data reported in this paper is EGAS00001000263. Provided as a separate file.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
Table S5 related to Figure 4. Analysis of p53 analysis and clinical features.
Provided as a separate file.
Table S6 related to Figure 5. ATRX analysis in osteosarcoma.
Table S7 related to Figure 5. Cancer gene mutations in osteosarcoma.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES Tumor Samples
Twenty high-grade intermedullary osteosarcoma samples with matched normal tissue from 19 patients were subjected to the whole genome sequence (WGS) analysis. The samples included 16 untreated primary and 4 metastatic tumors, the latter obtained from 3 patients, of whom two had metastatic disease at presentation and one had tumor Table 4 .
TP53 Immunostaining
The corresponding formalin-fixed, paraffin-embedded (FFPE) tissue blocks for each specimen were cut at 4 micron thickness. Immunohistochemical staining was performed using an antibody directed against p53 protein (DO-7, DAKO, 1:50) and processed with standard heat-induced epitope retrieval (Ventana CC1) and the Ventana IVIEW detection systems. p53 nuclear staining was scored using a previously published scoring system (Papai et al., 1997 ) with a minor modification as follows: samples with no staining cells were scored as negative; samples with <5% p53 immunopositive cells were scored as rare; samples with 5-25% immunopositive cells were scored as 1+; samples with 26-50% immunopositive cells were scored as 2+; samples with >50% immunopositive cells were scored as 3+.
TP53 and MDM2 Fluorescence In Situ Hybridization Studies
The fluorescence in situ hybridization (FISH) probe sets were designed using bacterial according to a modified Qiagen (Valencia, CA) extraction protocol. The probes were labeled by nick translation using a modification of the manufacturer's protocol (Life Technologies, Inc., Carlsbad, CA). FISH analysis was performed on 4 micron-thick FFPE tissue sections using the previously published methods .
Hybridization signals were evaluated in 200 interphase nuclei of each sample. FISH images were captured and processed as previously described .
Telomeres were analyzed in the discovery cohort using 3 different methods. The whole genome sequencing (WGS) data was analyzed for telomere length (described below) for all 20 tumors and matched normal tissue in the discovery cohort. Quantitative PCR (described below) was performed to validate the results from WGS analysis for all 10 tumors in the discovery cohort with ATRX mutations and an additional 4 samples with wild type ATRX to serve as controls. Matched normal DNA was used as internal control for each patient's sample. Telomere FISH (see below) was performed on all tissue samples in the discovery cohort that had available FFPE material (non-decalcified tumor tissue). All of the samples that were analyzed by telomere FISH were also analyzed for ATRX protein expression by immunohistochemistry (described below).
Whole-Genome Sequencing, RNA-Seq and Exome Seq
Using a paired-end sequencing approach, we sequenced DNA from 20 tumors and their matching germline control DNA with an average of 30× haploid coverage per genome.
Single nucleotide variations (SNVs) and insertions/deletions (indels) were identified independently algorithms by Washington University Genome Sequencing Center (WUGSC) and St. Jude Children's Research Hospital (SJCRH) using different approaches. The results generated were then compared and a final candidate SNV and indel list was developed for experimental validation.
At WUGSC, SNVs were found by Somatic Sniper that defines high quality somatic predictions as those sites with a somatic score greater than 40 and an average mapping quality greater than 40. The predicted SNVs are compared to the most current version of dbSNP (Sherry et al., 2001 ) (build 129-130). For SNVs, we require both positional and allele match. In addition we also compared the predicted SNVs to SNPs found in CEU and YRI trios as described (Ding et al.) . All predicted SNVs were filtered through a SNV false-positive filter developed at the Genome Institute that is based on a standard set of criteria including mapping quality score, average supporting read length, average position of the variant in the read, strand bias and the presence of homopolymer.
Indels were called using modified SAMtools (Li et al., 2009 ) indel-calling algorithm as described (Ding et al.) , Pindel (Ye et al., 2009 ) and GATK (Zerbino and Birney, 2008) .
At SJCRH, putative sequence variants including SNVs and indels were initially detected by running the variation detection module of Bambino (Edmonson et al.) using the following three parameters: (1) a high quality threshold for pooled tumor and matching normal bam files (min-quality=20, min-flanking-quality=20, min-alt-allelecount=3, min-minor-frequency=0, broad-min-quality=10, mmf-max-hq-mismatches=4, mmf-min-quality=15, mmf-max-any-mismatches=6; (2) a low quality threshold for pooled tumor and matching normal bam files (min-quality=10, min-flanking-quality=10, min-alt-allele-count=2, min-minor-frequency=0, broad-min-quality=10); and (3) a high tolerance for the number of mismatches for normal bam file alone (min-quality=20, minflanking-quality=15, min-alt-allele-count=2, min-minor-frequency=0, mmf-max-hqmismatches=15, mmf-min-quality=15, mmf-max-any-mismatches=20). In addition to
Bambino, putative indels were also found by a de novo assembly process which construct contigs using unmapped reads and re-map them to the reference genome followed by a Smith-Waterman alignment to detect indels. In this process, unmapped reads include (1) unmapped reads whose mate are mapped to the genome; (2) reads with indels in CIGAR (Compact Idiosyncratic Gapped Alignment Report) string; (3) reads with at least 4 highquality (quality value >=20) mismatches; and (4) reads with high-quality (quality value at least 20) soft-clipped bases in the CIGAR string. All putative sequence variants were further assessed to determine their accuracy and somatic original using the processes described below. Velvet (Zerbino and Birney, 2008) , BLAT (Kent, 2002) and SIM (Huang et al., 1990) were the three programs used for assembly, mapping, and Smith-Waterman alignment, respectively.
A putative somatic sequence mutation determined by SJCRH process was collected based on the following criteria: (1) the variant site is absent in the normal-only analysis; (2) Fisher's exact test P value indicates that the number of reads harboring nonreference allele is significantly higher in tumor; (3) the non-reference allele frequency in normal is <=5%; and (4) mutant alleles present in both orientations. Higher P value and absence of non-reference allele in normal is required for a variant to be considered somatic if it matches dbSNP build 130 or is located in an unmappable region (determined by recurrence of 75mers across the reference genome) or is inside a polynucleotide repeat. Substitution variants are classified into four categories based on combination of their P value and sequence quality scores: High quality, high P value; high quality, low P value; low quality, high P value; low quality, low P value. P value refers to the P value of Fisher's exact test comparing the distribution of the alternative allele in tumor and normal. High P value, P<0.05; low P value, 0.05<P<0.10. A final review process remaps and re-aligns the reads harboring the non-reference allele to the reference genome to filter potential false positive calls introduced by mapping in repetitive regions and alignment artifacts. For putative somatic indels, the review process re-aligns all reads in tumor and normal at the indel site to a mutant allele template sequence constructed by substituting the wild-type allele with the indel. Presence of reads in normal that cover the mutant allele is considered a germline variant. Structural variations including the 5 deletions in ATRX were detected using the CREST algorithm (Wang et al., 2011) and CONSERTING algorithm. The data have been deposited in EBI with accession number:
EGAS00001000263.
Paired-end reads from mRNA-seq were aligned to the following 4 database files using BWA (0.5.5) aligner (4) We used cghMCR (an R implementation of a modified version of GISTIC analysis (Aguirre et al., 2004) ) to find common regions of copy number alterations. To identify genes of significant DNA copy number alterations, we defined the genes with Segments Of Gain Or Loss (SGOL) scores above the 3 standard deviations of the mean SGOL scores of all 'gains' scores as significantly amplified genes. The genes with SGOL scores below the 3 standard deviations of the mean SGOL scores of all 'losses' scores were sselected as significantly deleted genes.
Sequence Validation
For enrichment of the regions containing putative alterations, genomic coordinates of the putative WGS targets were used to order Nimbelgen Seqcap EZ solution bait sets (Roche). The library construction and target enrichment was performed per manufacturer's instructions using repli-G (Qiagen) whole genome amplified DNA.
Enriched targets were sequenced on the Illumina platform using paired end 100 cycle sequencing. The resulting data was converted to FASTQ files using CASAVA 1.8.2
(Illumina) and mapped with BWA prior to pipeline analysis.
Statistical Methods
Kaplan-Meier method was used to estimate the overall survival and event-free survival curves. Log-rank test was performed to test the significant difference of survival curves between TP53 missense mutation group and the TP53 truncating mutation group in SAS version 9.2.
We used the MuSiC software (Dees et al., 2012) to identify significantly mutated base-level mutation rate for SVs in each tumor under the null hypothesis that SV breakpoints were distributed randomly within the genome and the number of tumors mutated by SVs for a specific gene follows the Poisson binomial distribution under the
Telomere Analysis
Telomere length was predicted in silico by counting the number of next-generation sequencing reads containing the telomeric-repeat sequence TTAGGG (Castle et al., 2010) . The resulting number of reads was normalized to the average genomic coverage, and the difference in diagnostic and germline telomeric sizes was calculated. Telomere length was validated in vitro in NBs expressing an ATRX aberration as described previously (Cawthon, 2002; O'Callaghan et al., 2008) . Briefly 15-20ng of diagnostic and germline WGA amplified DNA was subject to qPCR using two sets of primers in separate reactions, one to amplify telomeric sequence and one to amplify a common gene; 36B4 (RPLP0). Ct values obtained were compared to those of two standard curves, a telomeric standard curve performed on known quantities of a telomeric 84mer and one using an oligomer of 36B4 (RPLP0). All reactions were performed in triplicate with both tumor and germline DNA and both assays on the same plate. All reactions were carried out using Brilliant III Ultra-Fast SYBR Green master mix (Agilent) on a Stratagene Mx3000 thermal cycler using a melting temperature of 60 o C. This allowed us to determine the telomere length in Kb per diploid genome. The forward primer for telomere analysis was:
The reverse primer for telomere analysis was:
The forward primer for the internal control 36B4 (RPL0) gene was:
The reverse primer for the internal control 36B4 (RPL0) gene was:
The standard used to generate the standard curve for telomeres was:
The standard used to generate the standard curve for the internal control 36B4 (RPL0) was:
Formalin-fixed, paraffin-embedded tissues were cut into 4-µm-thick sections and immunostained with a polyclonal antibody against ATRX (1:600; Sigma-Aldrich) by using heat-induced epitope retrieval and Leica Polymer Refine Detection Kit (Leica Microsystems) on a Leica Bond system after 15-minute antibody incubation.
Telomere FISH
Interphase FISH was performed on 4-µm-thick, formalin-fixed, paraffin-embedded tissue sections. The Cy3-labeled TelG probe (PNAbio) was co-denatured with the target cells on a hotplate at 90 °C for 12 minutes. The slides were incubated for 48 hours at 37 °C and then washed in 4 M Urea/2× SSC at 45 °C for 5 minutes. Nuclei were counterstained with DAPI (200 ng/mL) (Vector Labs).
Tumor Purity Estimations
For germline heterogeneous SNPs, loss of heterozygosity (LOH) measures the absolute difference between the mutant allele fraction in tumor and that in germline sample (0.5).
LOH is the result of copy number alterations and/or copy neutral-LOH in tumor cells. template, we calculated a local alignment score within a 10-bp window of the breakpoint from SV and normal templates, and chose the template with higher score. In the end, the statuses of every read from all pair-wise comparisons were summarized to generate a consensus status. Any reads with conflicting statuses, i.e., called as SV in one run and non-SV in another run will be considered as "unknown". The SV mutant allele frequency was calculate by the ratio of number of SV reads to the total number of SV, non-SV, and unknown reads.
Tumor Heterogeneity Estimation
We used all validated autosomal SNVs satisfying the following criteria in heterogeneity analysis:
1) In copy neutral region (Log2ration between (-0.1, 0.1) in CNV analysis).
2) Not in regions with LOH (LOH value < 0.12 + min (0.08 purity*0.1).
3) With MAF > 0.05 or mutant allele count > 2.
We drew the kernel density estimate plot for MAFs of the qualifying SNVs using the density function in the stat package in R. For samples with at least 50 qualifying SNVs, we also estimated the number of significant peaks and the relative MAF component for each peak (peaks with less than 5 SNVs, peaks with less than 1% SNVs, and peaks with excessive variance were ignored). A sample with heterogeneity shows density peaks at a MAF smaller than 0.5 (the expected MAF assuming heterogeneous SNVs).
Kataegis Analysis
Kataegis analysis was performed on all validated Tier1-3 SNVs and SV breakpoints for each sample. The intermutation distance for a SNV was calculated as the distance to its nearest neighbor. For each SNV, its distance to the nearest validated SV breakpoint was also calculated. We defined microclusters of kataegis as clusters that contain at least 5
consecutive SNVs with inter-variant distance less than 10 kb. Mutant allele frequency (MAF) was estimated for SNVs with at least 20X coverage in tumor BAMs based on deep sequencing of custom capture validation.
We derived copy number of SNVs from the CONSERTING analysis. For each SNV, the CNV segment covering the SNV was identified and the corresponding CN was estimated after tumor purity adjustment and rounded to the nearest integer.
Statistical evaluation of chromothripsis in OS tumors analyzed by WGS
Chromothripsis was described as localized chromosome shattering and repair occurs in a single event. The initial criterion is oscillation between restricted CNV states ), which were found in 4 OS tumors in this study. Most recently, Korbel and Campbell (Korbel and Campbell, 2013) proposed four potential criteria for assessing chromothripsis: 1) clustering of breakpoints; 2) randomness of DNA fragment joins; 3) randomness of DNA fragment order; and 4) ability to walk the derivative chromosome. Since randomness of DNA fragment order (Criterion 3) was not entirely valid even in Korbel and Campbell's own analysis, we decided not to evaluate this feature. For the 4 tumors in Supplementary Table 5 , we performed Bartlett's goodness-of-fit test for exponential distribution to assess whether the distribution of SV breakpoints in each tumor departs from the null hypothesis of random distribution. A significant departure from random distribution supports clustering of SV breakpoints. To evaluate whether there is any bias in the DNA fragment joints categorized by the SV types (i.e. deletion, tandem duplication, head-to-head re-arrangements and tail-to-tail re-arrangements), we applied goodness-of-fit test separately for inter-and intrachromosomal events with a minimum of 5 SVs. A significant p value suggests biased fragment joins, which would not support chromothripsis. When both inter-and intrachromosomal data are available, we reported the lower p value to represent a more conservative assessment of the random distribution for DNA fragment joints.
The significant chromothripsis regions were chromosome 14 in SJOS002_D (p=2.09E-09), chromosome 17 in SJOS003_D (p=9.65E-05), chromosome 6 in SJOS005_D (p=1.75E-90) and chromosome 13 in SJOS010_M (p=2.21E-35).
